Senores Pharmaceuticals

569.15
+16.45
(2.98%)
ann
There are new updates from the company17 hours ago
Viewcross
right
Market Cap
2,621.14 Cr
EPS
13.67
PE Ratio
80.58
Dividend Yield
0.00 %
Industry
0.00
52 Week High
644.80
52 Week low
435.25
PB Ratio
3.30
Debt to Equity
1.28
Sector
0.00
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Senores Pharmaceuticals to Acquire Stake in Havix GroupToday
Senores Pharmaceuticals has announced plans to acquire 8,454 equity shares of Havix Group at a price of USD 160 per share. This acquisition represents a strategic move by Senores Pharmaceuticals to expand its portfolio or market presence.
neutral
Senores Pharmaceuticals to Acquire Equity Shares in Havix Group16 hours ago
Senores Pharmaceuticals has announced plans to acquire 8,454 equity shares of Havix Group at a price of USD 160 per share. This acquisition represents a strategic move by Senores Pharmaceuticals to expand its holdings or influence in the Havix Group.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
No data
Growth Rate
Revenue Growth
457.18 %
Net Income Growth
289.29 %
Cash Flow Change
-1,739.81 %
ROE
-23.80 %
ROCE
-50.08 %
EBITDA Margin (Avg.)
-51.25 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Dec 2024
Revenue
80
104
108
Expenses
64
80
77
EBITDA
16
24
31
Operating Profit %
19 %
22 %
25 %
Depreciation
3
4
4
Interest
3
3
6
Profit Before Tax
10
18
21
Tax
3
3
4
Net Profit
7
14
16
EPS in ₹
4.01
5.22
5.04

Balance Sheet

Balance Sheet
2022
2023
2024
Total Assets
59
131
622
Fixed Assets
7
27
235
Current Assets
27
51
251
Capital Work in Progress
8
35
97
Investments
15
17
0
Other Assets
29
53
289
Total Liabilities
59
131
622
Current Liabilities
10
52
248
Non Current Liabilities
13
34
143
Total Equity
37
46
232
Reserve & Surplus
28
36
174
Share Capital
9
10
31

Cash Flow

Cash Flow
2022
2023
2024
Net Cash Flow
2
-3
13
Investing Activities
-24
-48
-54
Operating Activities
-10
-1
-20
Financing Activities
37
46
87

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Promoter
66.66 %
45.76 %
45.76 %
FIIs
0.00 %
5.51 %
4.25 %
DIIs
0.00 %
18.61 %
11.78 %
Government
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
27.88 %
28.71 %
Others
33.34 %
2.23 %
9.49 %
No of Share Holders
177
43,707
43,707

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Acquisition
17 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release
7 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 26, 2025, 15:42
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 26, 2025, 15:42
Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient (API) Manufacturing Facility Of The Company
Feb 26, 2025, 15:36
Announcement Regarding Inauguration Of Second Active Pharmaceutical Ingredient (API) Manufacturing Facility Of The Company
Feb 26, 2025, 15:36
Announcement under Regulation 30 (LODR)-Acquisition
Feb 25, 2025, 19:16
Announcement under Regulation 30 (LODR)-Acquisition
Feb 25, 2025, 19:16
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 20, 2025, 22:13
Intimation For Change In The Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of The Company.
Feb 18, 2025, 15:42
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 03, 2025, 12:51
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jan 30, 2025, 11:55
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 24, 2025, 11:41
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 23, 2025, 19:13
Integrated Filing (Financial)
Jan 23, 2025, 18:11
Appointment of Secretarial Auditor
Jan 23, 2025, 18:05
Monitoring Agency Report for the quarter ended December 31 2024
Jan 23, 2025, 17:22
Statement Of Deviation/Variation If Any For The Quarter Ended December 31 2024.
Jan 23, 2025, 15:12
Media Release For Q3 And 9MFY25
Jan 23, 2025, 14:00
Results For Quarter And Nine Months Ended December 31 2024
Jan 23, 2025, 13:55
Board Meeting Outcome for Outcome Of Board Meeting Held On 23-01-2025.
Jan 23, 2025, 13:46
Intimation Under Regulation 30(6) Of SEBI (LODR) Regulations 2015.
Jan 20, 2025, 20:08
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Jan 13, 2025, 11:27
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 10, 2025, 19:48
Board Meeting Intimation for Considering And Approving Unaudited Standalone And Consolidated Financial Results Of The Company For Quarter And Nine Months Ended December 31 2024.
Jan 10, 2025, 19:35
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 09, 2025, 22:03
Closure of Trading Window
Dec 31, 2024, 19:13
Listing of Equity Shares of Senores Pharmaceuticals Ltd
Dec 30, 2024, 08:07

Company Filings to Exchanges

Technical Indicators

RSI(14)
Neutral
50.36
ATR(14)
Volatile
39.22
STOCH(9,6)
Neutral
61.15
STOCH RSI(14)
Neutral
40.68
MACD(12,26)
Bullish
0.86
ADX(14)
Weak Trend
12.07
UO(9)
Bearish
51.98
ROC(12)
Uptrend And Accelerating
7.16
WillR(14)
Neutral
-52.22